LFCR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

35.31M

+0.44%

-0.160

-65.96%

Estimates Revision

The market is revising No Change the revenue expectations for Lifecore Biomedical, Inc. (LFCR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 14.03%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.27%

In Past 3 Month

Stock Price

Go Up

+14.03%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Lifecore Biomedical Inc (LFCR.O) is -9.21, compared to its 5-year average forward P/E of -70.24. For a more detailed relative valuation and DCF analysis to assess Lifecore Biomedical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-70.24

Current PE

-9.21

Overvalued PE

225.71

Undervalued PE

-366.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

23.60

Current EV/EBITDA

21.21

Overvalued EV/EBITDA

42.18

Undervalued EV/EBITDA

5.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.67

Current PS

2.24

Overvalued PS

2.12

Undervalued PS

1.21

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LFCR News & Events

Events Timeline

No data

News

7.0

01-09Globenewswire

Integer Holdings Faces Shareholder Investigation Over Alleged Misstatements

7.0

01-05Globenewswire

CarMax Shareholder Investigation: Executives Allegedly Breached Duties

7.0

01-02Globenewswire

Cytokinetics Faces Shareholder Investigation Over Alleged Misleading Statements

People Also Watch

Frequently Asked Questions

What is Lifecore Biomedical Inc (LFCR) stock price today?

The current price of LFCR is 7.56 USD — it has decreased -2.7 % in the last trading day.

What is Lifecore Biomedical Inc (LFCR)'s business?

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

What is the price predicton of LFCR Stock?

Wall Street analysts forecast LFCR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFCR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Lifecore Biomedical Inc (LFCR)'s revenue for the last quarter?

Lifecore Biomedical Inc revenue for the last quarter amounts to 31.11M USD, increased 25.92 % YoY.

What is Lifecore Biomedical Inc (LFCR)'s earnings per share (EPS) for the last quarter?

Lifecore Biomedical Inc. EPS for the last quarter amounts to -0.29 USD, decreased -45.28 % YoY.

What changes have occurred in the market's expectations for Lifecore Biomedical Inc (LFCR)'s fundamentals?

How many employees does Lifecore Biomedical Inc (LFCR). have?

Lifecore Biomedical Inc (LFCR) has 406 emplpoyees as of January 10 2026.

What is Lifecore Biomedical Inc (LFCR) market cap?

Today LFCR has the market capitalization of 283.25M USD.